This document describes the Sultan Bin Khalifa International Thalassemia Award, which recognizes national and international institutions, individuals, researchers, and organizations that improve the quality of life for thalassemia patients. The award is organized by the Sultan Bin Khalifa Al Nahyan Humanitarian & Scientific Foundation and gives monetary prizes in various categories. Nominations are evaluated by local and international scientific committees using a multi-step selection process, and winners are announced at the Thalassemia International Federation conference held every two years.
Current Situation in Control Strategies and Health Systems in Asia - Sri Lanka by Rasnayaka M Mudiyanse, Senior Lecturer in Paediatrics at the University of Peradeniya and Consultant Paediatrician at the Teaching Hospital in Peradeniya.
CURRENT SITUATION IN CONTROL STRATEGIES & HEALTH SYSTEMS IN ASIA - CAMBODIA by PRAK PISETH RAINGSEY, MD, DND, MPH Director Preventive Medicine Department MINISTRY OF HEALTH
Thalassaemia is present among Australia's ethnically diverse population. There is no national registry or standardized antenatal screening policy. Estimates indicate around 326 patients with beta thalassaemia major nationally, though numbers may be higher without a registry. Diagnostic testing and genetic counseling are available through specialist centers and hospital laboratories nationwide.
Current Situation in Control Strategies and Health Systems in Asia - India by Roshan B.Colah, Scientist F- Deputy Director (SG), National Institute of Immunohaematology, Parel, Mumbai
Current Care of Thalassaemia Major Patients in Hong Kong, China by Vincent Lee, Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong
Prevention programmes for haemoglobinopathies appropriate for Asia – A policy perspective - by Anuja Premawardhena of the University of Kelaniya, Sri Lanka
Current Situation in Control Strategies and Health Systems in Asia - Sri Lanka by Rasnayaka M Mudiyanse, Senior Lecturer in Paediatrics at the University of Peradeniya and Consultant Paediatrician at the Teaching Hospital in Peradeniya.
CURRENT SITUATION IN CONTROL STRATEGIES & HEALTH SYSTEMS IN ASIA - CAMBODIA by PRAK PISETH RAINGSEY, MD, DND, MPH Director Preventive Medicine Department MINISTRY OF HEALTH
Thalassaemia is present among Australia's ethnically diverse population. There is no national registry or standardized antenatal screening policy. Estimates indicate around 326 patients with beta thalassaemia major nationally, though numbers may be higher without a registry. Diagnostic testing and genetic counseling are available through specialist centers and hospital laboratories nationwide.
Current Situation in Control Strategies and Health Systems in Asia - India by Roshan B.Colah, Scientist F- Deputy Director (SG), National Institute of Immunohaematology, Parel, Mumbai
Current Care of Thalassaemia Major Patients in Hong Kong, China by Vincent Lee, Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong
Prevention programmes for haemoglobinopathies appropriate for Asia – A policy perspective - by Anuja Premawardhena of the University of Kelaniya, Sri Lanka
Bone marrow transplantation for thalassemia in lower resource settings - The Cure2Children Foundation experience in Pakistan. By Dr Naila Yaqub, Assistant Professor, Bone Marrow Transplant unit, The Children hospital, PIMS, Pakistan
MRI-based Monitoring Tools for Iron Chelation by Pairash Saiviroonporn, Ph.D., Radiology Department, Faculty of Medicine Siriraj Hospital, Mahidol University
Understanding the molecular mechanisms leading to reactivation or derepression of γ-globin gene by Jim Vadolas, Cell and Gene Therapy Group, Murdoch Childrens Research Institute, Royal Children’s Hospital
Gene therapy aims to cure β-thalassemias by using lentiviral vectors to insert functional β-globin genes into hematopoietic stem cells. The first patient treated achieved long-term transfusion independence with stable multi-year expression of the corrected globin. Analysis found most genetically modified cells contained the vector integrated near the HMGA2 gene, though the majority of cells remained unmodified. Ongoing work continues to optimize the therapy.
This document discusses the multi-disciplinary care needs for patients with thalassaemia. Thalassaemia affects multiple organ systems over time as it progresses from a chronic anemia disease to one that impacts the heart, liver, endocrine system and more. It requires monitoring and treatment from specialists in cardiology, hepatology, endocrinology and others. The optimal approach is for patients to receive care at dedicated thalassaemia centers with a multi-disciplinary team that can coordinate treatment across specialties and properly manage the many complications that can arise for patients with this condition.
Treatment of patients with β-Thalassaemias focuses on improving outcomes through regular blood transfusions and iron chelation therapy to remove excess iron from previous transfusions. Advances in transfusion and chelation regimens have led to significantly improved survival rates over time. Maintaining low levels of iron overload through adherence to chelation therapy and monitoring of iron levels correlates strongly with reduced complications and improved long-term survival and outcomes for patients with thalassaemia major.
Genetic Screening and Prenatal Diagnosis of Thalassemias and Hemoglobinopathies in Taiwan Today by Ching-Tien Peng, MD, MPH, Superintendent & Prof. of The Children’s Hospital, China Medical University & Hospitals, Prof. of Biotechnology, Asia University, Taichung, Taiwan
Taiwan has a population of over 23 million people with a GDP per capita of $18,603. The country implemented a National Health Insurance program in 1995 that provides coverage for inpatient, outpatient, and limited home care. Thalassemia is prevalent in Taiwan, with carrier rates of 5-8% for various types. The country has a national prevention program that screens pregnant women and provides confirmatory testing and genetic counseling. Treatment for thalassemia major includes regular blood transfusions paid for by National Health Insurance as well as iron chelation therapy. Multidisciplinary expert centers provide coordinated care and management for patients.
Thalassemia in Viet Nam by Prof.Nguyen Anh Tri MD Ph.D Director - National institute of Hematology and Blood Transfusion President – Viet Nam Thalassemia Association
Current Situation in Control Strategies and Health Systems in Philippines by ERNESTO d’J. YUSON MD, Thalassemia Center of the Philippines, Balikatang Thalassaemia
Thalassemia in Laos: Situation Analysis by Dr. Sourideth Sengchanh, Dr. Alongkone Phengsavanh, Assoc. Prof. Dr. Khampe Phongsavat, University of Health Sciences, Vientiane, Laos. Presented by Assoc. Prof. Dr. Khampe Phongsavat.
Thalassaemia in Bangladesh by Dr. Waqar Ahmed Khan, MBBS, M.Phil who is Professor of Pathology, Bangladesh Institute of Child Health, Dhaka Shishu (Children) Hospital and President of Dhaka Shishu Hospital Thalassaemia, Dhaka, Bangladesh.
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Bone marrow transplantation for thalassemia in lower resource settings - The Cure2Children Foundation experience in Pakistan. By Dr Naila Yaqub, Assistant Professor, Bone Marrow Transplant unit, The Children hospital, PIMS, Pakistan
MRI-based Monitoring Tools for Iron Chelation by Pairash Saiviroonporn, Ph.D., Radiology Department, Faculty of Medicine Siriraj Hospital, Mahidol University
Understanding the molecular mechanisms leading to reactivation or derepression of γ-globin gene by Jim Vadolas, Cell and Gene Therapy Group, Murdoch Childrens Research Institute, Royal Children’s Hospital
Gene therapy aims to cure β-thalassemias by using lentiviral vectors to insert functional β-globin genes into hematopoietic stem cells. The first patient treated achieved long-term transfusion independence with stable multi-year expression of the corrected globin. Analysis found most genetically modified cells contained the vector integrated near the HMGA2 gene, though the majority of cells remained unmodified. Ongoing work continues to optimize the therapy.
This document discusses the multi-disciplinary care needs for patients with thalassaemia. Thalassaemia affects multiple organ systems over time as it progresses from a chronic anemia disease to one that impacts the heart, liver, endocrine system and more. It requires monitoring and treatment from specialists in cardiology, hepatology, endocrinology and others. The optimal approach is for patients to receive care at dedicated thalassaemia centers with a multi-disciplinary team that can coordinate treatment across specialties and properly manage the many complications that can arise for patients with this condition.
Treatment of patients with β-Thalassaemias focuses on improving outcomes through regular blood transfusions and iron chelation therapy to remove excess iron from previous transfusions. Advances in transfusion and chelation regimens have led to significantly improved survival rates over time. Maintaining low levels of iron overload through adherence to chelation therapy and monitoring of iron levels correlates strongly with reduced complications and improved long-term survival and outcomes for patients with thalassaemia major.
Genetic Screening and Prenatal Diagnosis of Thalassemias and Hemoglobinopathies in Taiwan Today by Ching-Tien Peng, MD, MPH, Superintendent & Prof. of The Children’s Hospital, China Medical University & Hospitals, Prof. of Biotechnology, Asia University, Taichung, Taiwan
Taiwan has a population of over 23 million people with a GDP per capita of $18,603. The country implemented a National Health Insurance program in 1995 that provides coverage for inpatient, outpatient, and limited home care. Thalassemia is prevalent in Taiwan, with carrier rates of 5-8% for various types. The country has a national prevention program that screens pregnant women and provides confirmatory testing and genetic counseling. Treatment for thalassemia major includes regular blood transfusions paid for by National Health Insurance as well as iron chelation therapy. Multidisciplinary expert centers provide coordinated care and management for patients.
Thalassemia in Viet Nam by Prof.Nguyen Anh Tri MD Ph.D Director - National institute of Hematology and Blood Transfusion President – Viet Nam Thalassemia Association
Current Situation in Control Strategies and Health Systems in Philippines by ERNESTO d’J. YUSON MD, Thalassemia Center of the Philippines, Balikatang Thalassaemia
Thalassemia in Laos: Situation Analysis by Dr. Sourideth Sengchanh, Dr. Alongkone Phengsavanh, Assoc. Prof. Dr. Khampe Phongsavat, University of Health Sciences, Vientiane, Laos. Presented by Assoc. Prof. Dr. Khampe Phongsavat.
Thalassaemia in Bangladesh by Dr. Waqar Ahmed Khan, MBBS, M.Phil who is Professor of Pathology, Bangladesh Institute of Child Health, Dhaka Shishu (Children) Hospital and President of Dhaka Shishu Hospital Thalassaemia, Dhaka, Bangladesh.
More from Thalassaemia International Federation (20)
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
- Video recording of this lecture in English language: https://youtu.be/RvdYsTzgQq8
- Video recording of this lecture in Arabic language: https://youtu.be/ECILGWtgZko
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...
Introduction to Sultan Bin Khalifa International Thalassaemia Award
1. SULTAN BIN KHALIFA INTERNATIONAL
THALASSEMIA AWARD
A Division of
H.H. SHEIKH SULTAN BIN KHALIFA AL NAHYAN
HUMANITARIAN & SCIENTIFIC FOUNDATION
Dr. Mahmoud Taleb Al Ali
Secretary General
2. H.H. Sheikh Khalifa Bin Zayed Al Nahyan
President of UAE
H.H. Sheikh Sultan Bin Khalifa Al Nahyan
Advisor to the President of UAE
Chief Patron of the Foundation
13. Sultan International Thalassemia Award
o Non-profit non-governmental organization
o Dedicated to value and support National/International
Institutions/Individuals making substantive efforts
and contributing to improvement of quality of life of
Thalassemia Patients
15. BOARD OF TRUSTEES
H.H. Sheikh Zayed Bin Khalifa Al Nahyan
Chairman
Mr. Panos Englesoz
Vice-Chairman
16. INTERNATIONAL SCIENTIFIC COMMITTEE
Prof. Demetris Loukopoulos
Prof. Nica Dr. Androulla
Capellini Eleftheriou
Prof. David Weatherall Dr. Erol Baysal
Prof. John Porter
Prof. George Prof. Suthat
Stamatoyiannopoulos Fuscharoen
17. AWARD CATEGORIES
INTERNATIONAL AWARDS NATIONAL AWARDS
oSultan Bin Khalifa Grand oMedical Institute or Centre of Excellence
International (USD 100,000) (AED 100,000)
oInternational Award for oInnovative Medical Research (AED 100,000)
Innovative Medical Research oOutstanding Physician (AED 35,000)
(USD 50,000) oOutstanding Nurse (AED 30,000)
oInternational Award for oOutstanding Personality for Social Support
Medical Institute or Centre of (AED 30,000)
Excellence (USD 20,000)
oInspiring Patient (AED 30,000)
oInternational Award for
oExtraordinary Parent (AED 30,000)
Thalassemia Patient/Parent
Society of Excellence oBest Research Publication (AED 20,000)
(USD 20,000) oBest Media Coverage (AED 20,000)
oInternational Personality of oPersonality of the Year Award*
the Year Award* oPhilanthropist of the Year Award*
oBest Supporting Organization*
oBest Media Group*
oTop Student in Medical Field*
*Non-monetary award
37. SELECTION PROCESS
Board of
Trustees
Local Scientific Inter. Scientific
Administration
Committee Committee
Sub Sub Sub Sub Sub Sub
Committee Committee Committee Committee Committee Committee
1 2 3 1 2 3
Application
38. SELECTION PROCESS
Board of
Trustees
Local Scientific Inter. Scientific
Administration
Committee Committee
Sub Sub Sub Sub Sub Sub
Committee Committee Committee Committee Committee Committee
1 2 3 1 2 3
Application
39. SELECTION PROCESS
Board of
Trustees
Local Scientific Inter. Scientific
Administration
Committee Committee
Sub Sub Sub Sub Sub Sub
Committee Committee Committee Committee Committee Committee
1 2 3 1 2 3
Application
40. SELECTION PROCESS
Board of
Trustees
Local Scientific Inter. Scientific
Administration
Committee Committee
Sub Sub Sub Sub Sub Sub
Committee Committee Committee Committee Committee Committee
1 2 3 1 2 3
Application
41. SELECTION PROCESS
Board of
Trustees
Local Scientific Inter. Scientific
Administration
Committee Committee
Sub Sub Sub Sub Sub Sub
Committee Committee Committee Committee Committee Committee
1 2 3 1 2 3
Application
42. SELECTION PROCESS
Board of
Trustees
Local Scientific Inter. Scientific
Administration
Committee Committee
Sub Sub Sub Sub Sub Sub
Committee Committee Committee Committee Committee Committee
1 2 3 1 2 3
Application
43. AWARD CEREMONY
o Winners announced during the
Thalassemia International Federation
conference held every two years.
o Official ceremony in Abu Dhabi